Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.40 |
| ▸ | BPTF | Q12830 | 2/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | CFD | P00746 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12101289 | 1.00 | F10 (0.53) | F10KLKB1SLC2A1BPTFCLK2 | |
| SCHEMBL12101325 | 0.89 | F10 (0.51) | F10KLKB1SLC2A1BPTFCFD | |
| SCHEMBL12101320 | 0.86 | F10 (0.54) | F10KLKB1CLK2CLK3DYRK1A | |
| SCHEMBL12101303 | 0.82 | F10 (0.52) | F10KLKB1CFD | |
| SCHEMBL13104190 | 0.82 | F10 (0.52) | F10KLKB1CFD | |
| SCHEMBL12101415 | 0.81 | F10 (0.52) | F10KLKB1CFD | |
| SCHEMBL12101343 | 0.81 | F10 (0.54) | F10KLKB1CFD | |
| SCHEMBL13104189 | 0.81 | F10 (0.54) | F10KLKB1CFD | |
| SCHEMBL14434252 | 0.80 | F10 (0.56) | F10KLKB1SLC2A1CFD | |
| SCHEMBL14434674 | 0.80 | F10 (0.53) | F10KLKB1SLC2A1CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051975-B1 | SUBSTITUTED PROLINAMIDES, PRODUCTION THEREOF AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-7807693-B2 | Substituted prolinamides, manufacturing, and the use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| US-7807693-B2 | Substituted prolinamides, manufacturing, and the use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20080139605-A1 | SUBSTITUTED PROLINAMIDES, MANUFACTURING, AND THE USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | US | disclosed |
| US-20080139605-A1 | SUBSTITUTED PROLINAMIDES, MANUFACTURING, AND THE USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139605-A1 | SUBSTITUTED PROLINAMIDES, MANUFACTURING, AND THE USE THEREOF AS MEDICAMENTS | PPID, PREP, P4HA1 | F10 2294/4885KLKB1 1925/4885SLC2A1 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.